2003•University of Groningen research database (University of Groningen / Centre for Information Technology)Requires access

Combined thalidomide and cyclophosphamide treatment for refractory or relapsed multiple myeloma. A prospective phase III study.

Sjoerd Hovenga, SMGJ Daenen, Jtm de Wolf, GW van Imhoff, Hanneke C. Kluin‐Nelemans, Edo Vellenga

Open publisher page 0 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Thalidomide, Medicine, Multiple myeloma, Refractory (planetary science), Cyclophosphamide, Lenalidomide, Internal medicine, Oncology

Back to paper search Browse research topics Original source

Combined thalidomide and cyclophosphamide treatment for refractory or relapsed multiple myeloma. A prospective phase III study. — Research Paper | ScholarLens